Top

Published in:

01-06-2013 | Correspondence

VE1 immunohistochemistry in pituitary adenomas is not associated with BRAF V600E mutation

Authors: Jan Sperveslage, Midea Gierke, David Capper, Jürgen Honegger, Bence Sipos, Rudi Beschorner, Jens Schittenhelm

Published in: Acta Neuropathologica | Issue 6/2013

Excerpt

Activating BRAF mutations are observed in malignant melanomas, pleomorphic xanthoastrocytomas, hairy cell leukemia, papillary thyroid carcinomas, colorectal cancer, ovarian cancer and ganglioglioma [1, 10, 11]. Generation of a monoclonal antibody specific for the BRAF V600E mutation (VE1) was published recently [3]. This antibody has been successfully validated for melanomas [5], lung adenocarcinomas [8] and thyroid carcinomas [2]. Although pituitary adenomas account for up to 10 % of all intracranial tumors [4], there is still a lack of data on VE1 immunostains in these tumors. In three studies in which BRAF in pituitary adenomas was examined by sequencing, a single V600E mutation was found in 145 cases [6, 7, 10]. …

Available only for authorised users

Andrulis M et al (2012) Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia. Am J Surg Pathol 36:1796–1800PubMedCrossRef

Bullock M et al (2012) Utilization of a MAB for BRAF(V600E) detection in papillary thyroid carcinoma. Endocr Relat Cancer 19:779–784PubMedCrossRef

Capper D et al (2011) Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 122:11–19PubMedCrossRef

Central Brain Tumor Registry of the United States (2012) statistical report, revised March 23. http://www.cbtrus.org/reports/reports.html

Colomba E et al (2013) Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing. J Mol Diagn 15:94–100PubMedCrossRef

De Martino I et al (2007) B-RAF mutations are a rare event in pituitary adenomas. J Endocrinol Invest 30: RC1–3

Ewing I et al (2007) A mutation and expression analysis of the oncogene BRAF in pituitary adenomas. Clin Endocrinol (Oxf) 66:348–352CrossRef

Ilie M et al (2013) Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients. Ann Oncol 24:742–748PubMedCrossRef

Jeong D et al (2012) Detection of BRAFV600E mutations in papillary thyroid carcinomas by peptide nucleic acid clamp real-time pcr: a comparison with direct sequencing. Korean J Pathol 46:61–67PubMedCrossRef

10.

Schindler G et al (2011) Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121:397–405PubMedCrossRef

11.

Ziai J, Hui P (2012) BRAF mutation testing in clinical practice. Expert Rev Mol Diagn 12:127–138PubMedCrossRef

Title: VE1 immunohistochemistry in pituitary adenomas is not associated with BRAF V600E mutation
Authors: Jan Sperveslage
Midea Gierke
David Capper
Jürgen Honegger
Bence Sipos
Rudi Beschorner
Jens Schittenhelm
Publication date: 01-06-2013
Publisher: Springer-Verlag
Published in: Acta Neuropathologica / Issue 6/2013
Print ISSN: 0001-6322
Electronic ISSN: 1432-0533
DOI: https://doi.org/10.1007/s00401-013-1118-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

VE1 immunohistochemistry in pituitary adenomas is not associated with BRAF V600E mutation

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 6/2013

Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells

Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays

BRAFV600E mutation is a negative prognosticator in pediatric ganglioglioma

Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease

Recessive desmin-null muscular dystrophy with central nuclei and mitochondrial abnormalities

Clathrin adaptor CALM/PICALM is associated with neurofibrillary tangles and is cleaved in Alzheimer’s brains